ArticleResearch and practice in thrombosis and haemostasis2026
The Thromboembolism Heparinization and AntithrombiN Observational Study (THANOS-1).
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute pulmonary embolism (PE) affects both hemodynamics and the clotting system, and changes in clotting protein activity may affect the effectiveness of anticoagulation. For example, PE may represent an acute, acquired antithrombin (AT)-deficient state, which may limit heparin effectiveness. However, the incidence and clinical effects of acquired AT deficiency after PE are not known. Objectives: Our primary aim was to calculate the proportion of patients with PE and acquired AT deficiency, defined a priori as <80% functional activity. We also analyzed <90%, <100%, and <110% AT activity. Secondary aims were to identify clinical factors and outcomes associated with acquired AT deficiency. Methods: We performed a prospective, observational study of patients diagnosed with acute PE without contraindications to heparin anticoagulation. We obtained blood within 24 hours after positive PE imaging and measured AT activity. Outcomes were culled from the medical record. Results: We analyzed 200 patients. Mean age was 62 ± 16 years, and 120 (60%) were men. Fifty-four (27%) patients had <80%, 111 (56%) <90%, and 159 (80%) <100% AT activity. Low AT activity (<80%) was associated with longer hospital length of stay ( Conclusion: Acquired AT deficiency is common after acute PE, occurring in at least one-quarter of all patients. Low AT levels are associated with adverse clinical outcomes, intensive care unit admission, and longer hospital length of stay, but whether this is related to subtherapeutic anticoagulation is not clear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.